Nearly 70% of Phase II and III clinical trials experience delays, averaging an additional 16 months. Every delay in introducing new drugs means longer development cycles, escalating R&D costs and threats to your competitive advantage.
You’re dealing with regulatory checklists and uncertainty, scalability challenges, and supply chain disruptions. All of this unpredictability is not good for your organizational goals or your stress levels.
If only there was a way to navigate low predictability and speed up drug development while also improving outcomes.
The right Contract Development and Manufacturing Organization (CDMO) services can actually grant all three wishes.
CDMO services eliminate these bottlenecks, aligning expertise, infrastructure, and regulatory depth to fast-track commercialization.
| Challenge | How CDMO Services Solve It |
| Project Complexity | Streamline process development from molecule synthesis to clinical trials, ensuring scalability from the start. |
| Regulatory Uncertainty | Maintain compliance with CMC requirements, regional health authorities, and cGMP guidelines for smooth approvals. |
| Supply Chain Bottlenecks | Offer flexible manufacturing capacity, technology transfer support, and risk-mitigated supply chains to prevent disruptions. |
| Lack of Project Visibility | Provide real-time dashboards, milestone tracking, and adaptive workflows for better control and faster iteration. |
| Cost-Related Hurdles | Optimize process efficiency to reduce total cost of ownership without compromising quality or commercial viability. |